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Prophylaxis of venous thromboembolism 
in knee replacement surgery
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ABSTRACT
Venous thromboembolism (VTE) is still a frequent and sometimes severe complication after knee replacement surgery. Both 
pharmacological and non-pharmacological measures have been widely used to decrease VTE risk.   Non pharmacological 
treatment include measures directed to decrease the effects of blood stasis, intermittent pneumatic compression 
device (IPCD) and graduated compression stockings, and mechanical devices. Pharmacological prophylaxis of venous 
thromboembolism (VTE) is associated with a more significant decrease in the incidence of  deep venous thrombosis (DVT) 
and related complications after knee arthroplasty however anticoagulation   may increase the risk of postoperative bleeding 
and related complications, in particular the need for re-intervention. Aim of present review was to suggest practical approach 
to DVT prophylaxis in patients undergoing knee arthroplasty. 
Although parenteral drugs (low dose unfractionated heparin, low molecular weight heparin and fondaparinux) are the more 
frequently employed agents, limited compliance may be a concern. Recent studies suggest that direct oral anticoagulants, 
antithrombin and anti Xa agent, might be a useful alternative although safety may limited by an higher rate of  local bleeding.
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INTRODUCTION
Despite widespread use of antithrombotic prophylaxis the 
risk of deep venous thrombosis (DVT) after major orthopedic 
surgery is still not negligible [1,2].  DVT in these patients 
is frequently distal, asymptomatic  and diagnosed only by 
routine ultrasonography.  Usually the thrombus lyses with 
complete recovery.  Late pulmonary embolism however has 
been reported  even 40 days after surgery  [3-5]. At present no 
clear indication about the need for prolonged anticoagulation 
in small distal DVT   has been provided.
In an observational study Wang et al [6] reported that 160 
out of 359 patients developed distal DVT after TKR.  Eighty 
three (52%) involved the gastrocnemius and soleus muscular 
veins: 38 (46%) were isolated muscular DVT and 45 (54%) 
involved muscular branches and major leg veins.  Rates of 
clinical symptoms, late DVT, thrombus propagation and 
pulmonary embolism in patients with isolated muscular DVT 
were comparable between patients with isolated muscular 
DVT in comparison to patients with DVT in the major leg 
veins and patients with combined lesions [7].  
The incidence of symptomatic DVT is comprised between 
1.5-10% of patients undergoing knee artrhoplasty, while  fatal 
pulmonary embolism is relatively uncommon (0.5 to 1.5%) 
[1,8].  These data are confirmed by a systematic review that 
reported an incidence of VTE of 1.09% for knee surgery ( 
DVT 0.63% , pulmonary embolism –PE- 0.27% ) in patients 
in adequate drug prophylaxis [8]. A recent paper from 
Waitemata District Health Board – New Zealand – reports 
in a 4 year period a cumulative incidence of symptomatic 
VTE within 90 days of surgery of 3.29% [9]. The median 
time from surgery to diagnosis was 7 days. Deep vein 
thrombosis comprised 75% of cases, 77.6% distal and 23.2% 
proximal. Pulmonary embolism comprised 26.5% of VTE; 
47.7% had right heart strain on computed tomography/
echocardiography. Of patients developing VTE, 85.5% had 
pharmacological thrombo prophylaxis - aspirin 73%, LMWH 
20 mg 16%, LMWH 40 mg 16%, therapeutic LMWH 
3%, unfractionated heparin twice daily 1%, and warfarin 4%; 
75.6% received mechanical prophylaxis, while 4% of patients 
received no prophylaxis.
The main limitation of pharmacologic VTE prophylaxis is 
the risk of bleeding and related complications, in particular 
the need for re intervention. Major bleeding following TKR 
has been estimated between 1 and 3 percent.   These data 
however suffer from the limitation of the   variability in the 
definitions of bleeding used in published literature and few 
data in control patients. 
PATHOPHYSIOLOGY 
Knee replacement surgery   is associated with trauma to the 
soft tissues and bone with release of  cytokines and other 
pro-coagulant factors  [10].  Excessive release of tissue factor 
from  injury to the vascular wall leads to generation of large 
amounts of thrombin, which  favors platelet activation and 
thrombus formation [11].
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Finally blood venous stasis occurs as a result of several 
different factors: immobilization, edema, poor calf muscle 
pump and mechanical haemostatic devices used in surgery 
room.   Manipulation of the limb and the use of a tourniquet 
in patients undergoing TKA also contribute to venous stasis. 
[12].  VTE risk is highest in the first days after surgery, on 
average 7 days after TKA in comparison to 17 days after THA 
[1].   Early discontinuation of pharmacological prophylaxis 
favors extension of preexistent asymptomatic thrombosis or 
development of new thrombotic events.
The risk to develop DVT is significantly higher in patients 
undergoing knee replacement in comparison to both hip 
replacement and treatment of hip fracture [13-14] with 
a 4:1 ratio between distal and proximal thrombosis.  Age, 
underlying pre-existing diseases (cancer, obesity, previous 
DVT, thrombophylic conditions including those genetically 
determined ) , injury related factors and finally factors related 
to medical procedures significantly influence DVT risk [15].
Female sex and previous DVT were the more relevant risk 
factors for DVT independently from the drug used for 
pharmacological  prophylaxis  in the ORTHO-TEP study 
[16] . In a study by Kang et al [17] DVT was detected 
by B-mode ultrasonography performed 7 days after TKR 
in 175/1025 patents aged >75 years. Diabetes (P = 
0.014), high body mass index (BMI) (P = 0.003) and 
hyperomocysteinemia (P < 0.001) were significantly more 
frequent in the thrombus group. A significantly greater 
proportion of patients in the non-thrombus group had early 
postoperative activity (P < 0.001) and used a foot pump 
(P < 0.001). Operative duration was significantly longer in 
the thrombus group (P = 0.012). DVT was more frequent 
in bilateral than unilateral knee arthroplasty (P < 0.01). 
Multivariate logistic analysis revealed BMI, long operative 
duration, bilateral knee arthroplasty, and time to the activity 
after the operation to be predictive factors of DVT. At 
6-month follow-up in DVT  group, 4.7% of patients had 
pulmonary embolism and 18.8% had recurrent DVT. 
ProhPylaxis of DVT –PE 
In patients undergoing major orthopaedic surgery 
pharmacological and non-pharmacological measures are 
available for VTE prophylaxis.  At present parenteral agent, 
low dose unfractionated heparin (UH) , low molecular 
weight heparins (LMWH)  and fondaparinux are mainly 
used for drug prophylaxis.  Direct oral anticoagulants may 
be indicated in elective surgery in patients with expected 
poor adherence to parenteral route. Non pharmacological 
treatment include measures directed to decrease the 
effects of blood stasis, intermittent pneumatic compression 
device (IPCD) and   graduated compression stockings, and 
mechanical devices, IVC filters to avoid migration of eventual 
emboli to pulmonary circulation. IPCD and   graduated 
compression stockings anyway should be considered as 
adjunctive measures or used when contraindications exist 
to drug prophylaxis.
Low dose unfractionated heparin 
Low dose subcutaneous unfractionated heparin (UH has 
been widely used  for VTE prophylaxis before 1990. At 
present indication for low dose unfractionated heparin are 
limited, as clear evidence has been provided of superiority 
of LMWH [18].  In advanced renal failure ( creatinine 
clearance < 30 ml/min )  UH may instead of  LMWH in 
order to decrease haemorrhagic  risk.
Low molecular weight heparin ( LMWH) 
LMWH at present are the drugs of choice for pharmacological 
prophylaxis of DVT in orthopaedic surgery  [19-21].  After 
TKR treatment decreases by more than 50% the risk of 
post-operative asymptomatic DVT in comparison to no 
prophylaxis. Several studies have clearly demonstrated the 
superiority of LMWH in comparison to UH and adjusted 
dose warfarin with a similar, or superior in the case of 
warfarin, safety profile [22-24].   The risk for heparin induced 
thrombocytopenia ( HIT)  is lower with LMWH than 
with UH  [25].  Effects on symptomatic DVT or PE were 
not significantly different when LMWH was compared to 
fondaparinux, however the latter showed an higher bleeding 
rate leading to re-intervention [26-29]. 
Each LMWH has a specific molecular weight distribution 
that influence anticoagulant activity, duration of action, 
and renal clearance, so each agent must be considered a 
unique drug and one product cannot always be substituted 
for another (table 1).  
Table 1. LMWHs available  for DVT prophylaxis 
Active 
principle Standard dosage 
Dalteparin 5.000 IU before surgery , thereafter 5000 IU /day
Enoxaparin
40 mg (4000 IU) 12 h  before surgery, thereafter  
40 mg daily  ( european dose ) .  30 mg ( 3000 IU)  
before surgery, thereafter  30 mg b.i.d
Nadroparin
38 IU /kg 12 h before  surgery and 12 hours after.  38 
IU /kg for the next  3 days , then increase the dose to 
57 IU/day
Reviparin 4200 IU  before surgery , thereafter 4200 IU /day
At present no clear evidence has been provided on the optimal 
dose to be employed nor regarding efficacy difference among 
different molecules. For enoxaparin   European approved 
regimen is 40 mg (4000 IU) once –daily, US regimen is 30 
mg b.i.d.  Dose for patients with decreased renal function 
must be adjusted in relation to creatinine-clearance. 
Duration of treatment, initially limited to 10-14 days , after 
the demonstration of a non negligible  risk of DVT after 
hospital discharge  has been extended over 30 days [30]. 
Fondaparinux 
Fondaparinux , a synthetic drug,  indirectly  inhibits 
activated factor X  through an high affinity binding  with 
antithrombin. Only one study examined the effects of 
fondaparinux in comparison to placebo [31].  Although a 
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decrease of PE was reported , other end –points were not 
significantly affected and , due to increased bleeding risk 
, it was impossible to  assess a beneficial effect on overall 
mortality. Results from 4 randomized studies comparing 
fondaparinux to enoxaparin were reported by Turpie et al 
[32].  The original primary efficacy end point consisted of a 
composite of deep-vein thrombosis detected by mandatory 
bilateral venography, documented symptomatic deep-vein 
thrombosis, or pulmonary embolism up to day 11. The 
incidence of VTE was 13.7% (371 of 2,703 patients) in 
the enoxaparin group compared with 6.8% (182 of 2,682 
patients) in the fondaparinux group, with a risk reduction 
of 55.2% in favour of fondaparinux.
ORTHO-TEP registry compared the efficacy and safety 
of fondaparinux and LMWH in 3819 patients undergoing 
major orthopaedic surgery [16]. The main limitation of the 
study was its retrospective nature and the comparison of two 
different periods, the first  in which LMWH ( 3000-6000 
aX U)  and in the second with fondaparinux 2.5 mg used as 
thromboprophylaxis ,. Symptomatic DVT occurred in 4.1% 
of patients treated with LMWH in comparison to 5.6% in 
patients treated with fondaparinux. No significant difference 
was found between the two regimens in the incidence of 
pulmonary embolism and death. Despite similar overall 
incidence of bleeding  the need for surgical revision was lower 
with fondaparinux. At multivariate analysis previous VTE 
and female sex were associated with an increased risk of DTV. 
Vitamin K antagonists 
In United States adjusted dose warfarin is still used for DVT 
prophylaxis  in orthopaedic surgery     [33-34]. Extended 
vitamin K antagonists treatment ( > 4 weeks)  after THA 
was associated with a 4.6% absolute  decrease of VTE with 
a small increase in the risk of bleeding [35]. 
Aspirin
Studies on the effects of aspirin in DVT  prophylaxis  failed 
to demonstrate a favourable effect  in patients undergoing 
THA, TKR or finally treatment for hip fracture [36-37]. It 
must be emphasized that  serious methodological limitations 
impair a correct interpretation of these studies.  Raphael et 
al [38]  analyzed retrospectively a  total of 28,923 patients 
underwent THA or TKA  between January 2000 and June 
2012.  Patients were treated with   either aspirin (325 mg 
twice daily; 2800 patients) or warfarin   (26,123 patients). 
The overall symptomatic PE rate was lower (p < 0.001) 
in patients receiving aspirin (0.14%) than in the patients 
receiving warfarin (1.07%). This difference did not change 
after matching. The aspirin group also had significantly 
fewer symptomatic DVTs and wound-related problems. 
Jiang et al [39]  randomized  120 patients undergoing 
TKA to  aspirin combined with mechanical measures 
postoperatively (group A) , and respectively  low-molecular-
weight heparin (LMWH) sodium and rivaroxaban 
sequentially in combination with mechanical measures 
(group B).  Postoperatively DVT was detected in 10 of 60 
patients in group A (16.7%,) compared with 11 of 60 in group 
B (18.3%)  (P = 0.500). There were no cases of symptomatic 
VTE or death during the follow-up period. Patients in group 
A had the lower blood loss index as compared with patients 
in group B. The cost of VTE prevention analysis indicated a 
cost reduction using aspirin in group A compared with using 
LMWH and rivaroxaban in group B.
Direct oral anticoagulants 
In the last decade several oral direct anticoagulant have 
been introduced in clinical practice.  These agents have 
predictable anticoagulant effect, limited drug or food 
interactions and  therefore  may be administered at fixed 
doses without the need for regular laboratory monitoring 
and dose adjustments. Dabigatran exilate is a selective 
thrombin inhibitor while  apixaban , rivaroxaban and 
edoxaban are  direct Xa factor inhibitors (figure 1). These 
drugs differ for pharmacological and pharmacodynamics 
characteristics. Clinical studies, usually, have compared 
these drugs in TKA against enoxaparin at US or Europe 
dosages (respectively 3000 IU -30 mg – bi.d. and 4000 
IU daily).  Most published trials have a similar primary 
end point e.g. combined symptomatic or asymptomatic 
(diagnosed by venography) DVT, non fatal pulmonary 
embolism and all cause mortality.  A higher compliance after 
hospital discharge has been reported in comparison to low 
molecular weight heparin. Potential safety concerns must 
to be cleared by time.  Dabigatran is a substrate for efflux 
transporter P –gp: administration in association with  a P-gp 
inhibitor (amiodarone , verapamil, quinidine, ketokenazole, 
dronedarone )  may increase intestinal absorption increasing 
blood levels  and the risk of bleeding. Conversely P-gp 
inducers (rifampicin , carbamazepine and phenytoine ) may 
decrease plasma concentrations of dabigatran.   Apixaban 
and rivaroxaban are substrates of CYP3A4 / 5 and P-gp 
transporters.  Concomitant administration of  inhibitors 
of these systems such azole antifungine , HIV protease 
inhibitors may lead to increase of anticoagulation. By 
converse inducers of these systems decrease plasma levels 
of apixaban and rivaroxaban.  No significant increase of 
bleeding rate has been demonstrated with concomitant use 
of aspirin or NSAID  in patients treated with dabigatran 
both at 150 and 220 mg doses. 
Figure 1. Mechanism of action of new anticoagulants
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Anti thrombin agent
Dabigatran etexilate is a pro-drug quickly converted  in 
dabigatran by cytochrome P-450–independent esterases. 
Anticoagulant effect of dabigatran is reated to  a powerful 
reversible direct competitive inhibitor of both free and clot 
included thrombin.  Onset of action is prompt,  it has a 
consistent anticoagulant effect. The half-life ranges between 
12 and 17 h [40] but since  kidney excretion accounts for 
85% elimination ,  half-life does increase significantly also in 
patients with moderate renal failure ( creatinine clearance 
< 50 ml/min ).  
Two large randomized trials compared  dabigatran etexilate 
75 mg or 110 mg within 1 to 4 hours of surgery followed 
by 150 or 220 mg daily thereafter to  enoxaparin 40 mg on 
the day prior to surgery and daily thereafter  in patients 
undergoing elective major orthopedic surgery. In the RE-
MODEL trial were included 2101 patients undergoing knee 
replacement [41] and duration of treatment was  6 to 10 days. 
Exclusion criteria were haemorrhagic diathesis and sever liver 
or kidney failure. Administration of COX-2 inhibitors and 
aspirin were allowed during treatment period.  Dabigatran 
etexilate at 150 and 220 mg was statistically non-inferior 
to enoxaparin in the combined end point of  symptomatic 
or asymptomatic (diagnosed by venography at the end of 
treatment period ) DVT  , non fatal pulmonary embolism 
and all cause mortality. In RE-MODEL study symptomatic 
VTE occurred in 2.6% and 3.8 % at dabigratran dosage of 
220 mg and respectively 150 mg  in comparison to 3.5% of 
enoxaparin.   In REMOBILIZE study [42] dabigatran (150 
or 220 mg) was compared to enoxaparin (30 mg b.i.d.) for 
prevention of VTE after TKR. At variance with other studies 
enpaxaparin was superior to dabigatran.  However better 
results obtained with enoxaparin may be explained by the 
higher doses employed and by a later start of treatment with 
dabigatran (12 hours after surgery). 
A decreased dose (150 mg daily) must be prescribed in 
patients aged > 75 years or with impaired renal function 
(creatinine clearance between 30 and 60 ml/min) or treated 
with P-glycoprotein inhibitors (verapamil , amiodarone or 
quinidine ). 
Activated X factor inhibitors
Rivaroxaban is an  active direct inhibitor of coagulation 
Factor Xa. Maximal inhibition of factor Xa occurs three 
hours after a dose. Although effects lasts 8–12 hours  factor 
Xa activity does not return to normal within 24 hours so 
once-daily dosing is advised.  
The effects of rivaroxaban in orthopedic surgery have 
been examined RECORD studies.  In this group of trials 
primary composite efficacy endpoint was any DVT, 
nonfatal PE, or death from any cause. The RECORD 
3 ( 2531 patients ) study [43] showed that rivaroxaban 
started postoperatively and administered for 10-14 days 
was significantly more effective than enoxaparin 40 
mg /day started preoperatively in patients undergoing TKA.
The absolute risk reduction of the primary endpoint was 9.2% 
at two weeks in RECORD 3.  Safety profiles were similar 
between the two drugs. 
  Rivaroxaban was compared with enoxaparin 30 mg b.i.d , 
both started postoperatively and continued for 10–14 days 
in patients undergoing TKR in RECORD 4 trial  [44]. 
Incidence of primary efficacy outcome at day 17 after surgery 
were respectively 6.9% and 10.1% in patients randomized 
to rivaroxaban or enoxaparin.  After introduction of NICE 
guidelines administration of rivaroxaban was associated, in 
comparison to an historical control group, with  a significant 
decrease of symptomatic  confirmed pulmonary embolism 
( 2/266 vs 24/596 , p=0.0084) but at the expense of a 
significant increase of complications at surgical site [45]. 
The significant decrease of total DVT and all cause mortality 
(HR 0.46, 95% CI 0.39-0.54), was obtained however at the 
expense of  a significantly higher risk of significant bleeding 
and a trend towards an higher risk of major bleeding   ( RR 1.25 
, 95% CI 1.05-1.49). A recent retrospective study  compared 
369 patients receiving simultaneous combined mechanical 
and pharmacological thromboprophylactic modality and 385 
patients receiving sequential combined modality with early-
mechanical compression treatment followed by rivaroxaban 
2 days later after primary total knee arthroplasty surgery [46]. 
The incidence rates of proximal and distal DVT tested on 
the 2nd postoperative day, had no significant difference in 
the sequential group (4.16%) compared with those (3.25%) 
in the simultaneous group. No difference was found in the 
incidence rate of proximal and distal DVT on the 5th week 
between groups. No pulmonary embolism occurred. The 
mean volume of wound drainage in the sequential group was 
343 mL which was 98 mL lesser than in the simultaneous 
group (p < 0.001). The use of the mechanical compression 
method alone during the early-postoperative 48 hours, then 
followed by rivaroxaban then until the 5th week had the 
same antithrombotic effects and reduced the postoperative 
wound drainage volume as compared with simultaneous 
combined modalities.
Apixaban 
Apixaban is a reversible inhibitor of  activated X factor. 
Apixiban half life is close to 12 hours. The drug is  cleared 
through hepatic and renal route , the last contributing 
for 27%.  Daily dosage is 2.5 mg b.i.d.  The effects of 
apixiban in major orthopedic surgery were examined by 
the ADVANCE trials. In ADVANCE 1  apixaban 2.5mg 
b.i.d. was compared to enoxaparin (30 mg every 12 hours 
started after surgery) in 3195 patients undergoing TKA [47]. 
Treatment were administered  for 10-14 days. Primary end 
point (symptomatic or asymptomatic DVT, non fatal EP 
and overall mortality)  was reached in 9% of  apixiban group 
in comparison to 8.8% in enoxaparin group.  Bleeding was 
less frequent with apixiban than with enoxaparin - 0,7% vs. 
1.4% - (P = 0.053). 
ADVANCE 2 trial (3057 patients) compared apixaban with 
enoxaparin in patients undergoing TKA.   Primary efficacy 
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outcome incidence was 15.1% in the apixaban group and 
24.4% in the enoxaparin group (relative risk 0.62, 95% 
CI 0.51–0.74) [48].  In apixaban group proximal DVT, 
symptomatic nonfatal PE, and VTE-related death occurred 
in 1.1% of patients vs. 2.2% of those given enoxaparin 
(relative risk 0.50, 95% CI 0.26–0.97).  The incidence 
of bleeding was lower with apixaban in comparison to 
enoxaparin (P = 0.09)
A metanalysis of the ADVANCE studies showed that 
apixaban (2.5 mg b.i,d,)  compared to enoxaparin 
significantly decreased total DVT and all cause mortality (HR 
0.46, 95% CI 0.39-0.54).  However   the risk of symptomatic 
VTE was not significantly different (RR 0.81, 95%CI 0.41-
1.66, p= 0.57). Otherwise the administration enoxaparin was 
associated with an higher incidence of   bleeding requiring 
reoperation.  The reported   lower risk of major bleeding 
and significant bleeding  reported for apixaban  is limited 
by the fact that    drop in haemoglobin was not calculated 
in comparison to baseline values  but on immediate post-
operative haemoglobin ,  thus effective bleeding effects may 
be underestimated. 
Edoxaban
Limited experience has been provided with edoxaban 
in elective orthopaedic surgery.  STARS E-3 compared 
edoxaban ( 30 mg once daily started 6-24 hours after surgery ) 
wit enoxaparin 20 mg b.i,d, in 746 patients  undergoing TKA 
[49]  In STARS E-3  edoxaban decreased DVT in comparison 
to enoxaparin  ( 2.4 vs 6.9%).  Bleeding rate did not differ 
between the two drugs. Recently were published  data about 
300 patients undergoing TKA treated with  edoxaban  15 
mg , enoxaparin 20 mg b.i.d and fondaparinux 1.5 mg once 
a day  for a period of 14 days [50 ].  Edoxaban resulted 
more efficient in comparison to the other two prophylaxis 
regimens.  A randomized study evaluated the effectiveness of 
a  A-V Impulse System foot pump associated with edoxaban 
in the prophylaxis of  DVT after TKA [51]. The authors 
did not find any significant difference in primary outcomes 
(any DVT as detected by bilateral ultrasonography up to 
postoperative day 10 and pulmonary embolism PE up to 
postoperative day 28 )  and  safety outcomes ( bleeding and 
death of any cause up to postoperative day 28).
Management of bleeding 
Specific antidotes for NAO are in development and 
idarucizumab , a drug-specific antidote targeted to 
reverse the direct thrombin inhibitor dabigatran has been 
demonstrated efficacy and safe in animal models [52]  and 
in healthy volunteers [53] .  Idarucizumab administration 
i s  a s soc ia ted  wi th  immediate ,  complete ,  and 
sustained reversal of dabigatran-induced anticoagulation 
in healthy men, and was well tolerated with no unexpected 
or clinically relevant safety concerns. Andexanet alfa is a 
class-specific antidote targeted to reverse the oral direct 
factor Xa inhibitors as well as the indirect inhibitor, 
enoxaparin. Ciraparantag is a universal antidote targeted to 
reverse the direct thrombin and factor Xa inhibitors as well 
as the indirect inhibitor, enoxaparin.  At present, waiting 
clinical introduction of  drug antidotes ,  the management 
of bleeding should be guided by location  and severity of 
haemorrhage. Drug discontinuation and local compression, 
when possible, should be immediately adopted to stop 
bleeding.  In case of minor bleeding (haematuria or epistaxis) 
resuming drug after resolution of bleeding may be sufficient. 
In patients with major bleeding maintaining diuresis, 
administration of charcoal ,  transfusion of red blood cells 
and  fresh frozen plasma  may be used . Limited evidence 
exist that prothrombin complex concentrates, activated 
prothrombin complex concentrates  (FEIBA) and  rVIIa 
factor ,  may contribute to reversing the anticoagulant effects 
of   Xa factor inhibitors in patients with severe hemorrhagic 
complications. 
T I M I N G  O F  D R U G  A D M I N I S T R AT I O N  F O R 
THROMBOPROPHYLAXIS 
Timing of  the first dose of anticoagulants in patients 
undergoing TKR  has not still clearly defined.  In TKR 
perioperative thromboprophylaxis , 2 hours before till to 
6 hours after surgery,  has been associated with increase 
of bleeding risk  [54]. Late treatment , beyond 12 hours , 
otherwise seems to be associated with an higher VTE risk. 
COMPARISON OF DIFFERENT METHODS 
Few studies compared the efficacy and safety of different 
antithrombotic  methods and/ or agents on venous 
thromboembolism (VTE) after unilateral total knee 
arthroplasty.   A recent study from China showed that 
aspirin, low-molecular-weight heparin, and rivaroxaban 
could effectively reduce the incidence of VTE after 
total knee arthroplasty, and their efficacy was similar [55]. 
Rivaroxaban  however had a higher incidence of bleeding 
complication suggesting again some concerns on its  safety. 
Bern et al [56] randomized 355 patients in three groups  A: 
variable dose warfarin (first dose on the night preceding 
surgery with subsequent target INR 2.0-2.5), B: 2.5 mg 
fondaparinux daily starting 6-18 h postoperatively, or C: fixed 
1.0 mg dose warfarin daily starting 7 days preoperatively. All 
treatments continued until bilateral leg venous ultrasound 
day 28 ± 2 or earlier upon a VTE event.  Two patients in Arm 
C had asymptomatic distal DVT. One major bleed occurred 
in Arm B and one in Arm C (ischemic colitis). Fixed low dose 
warfarin started preoperatively was equivalent to two other 
standards of care under study (95 % CI: -0.0428, 0.0067 for 
both) as VTE prophylaxis.  
A metaanalysis of three studies involving 11,659 patients, 
the risk of symptomatic DVT (pooled OR 0.38, 95% CI 
0.16-0.90, , p=0.03) and bleeding (pooled OR 0.87, 95% CI 
0.77-0.99, p=0.03) was less in apixaban group compared to 
the enoxaparin group [57]. However, it was interesting to 
note that on subgroup analysis, the risk of PE was higher 
with apixaban when used for thromboprophylaxis in knee 
replacement surgery (pooled OR 2.58, 95% CI 1.10-6.04, 
p=0.03).
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VTE PROPHYLAXIS IN TKR IN HAEMOPHILIA
A debated point is the need of a VTE prophylaxis in patients 
affected by Haemophilia undergoing orthopaedic surgery 
[58]. 
Haemophilia is a X-linked disease characterized by an 
inherited lack of coagulative factors as factor VIII or IX 
associated with a high risk of haemorrhages. Due to the 
recent improvements in the prevention of bleedings by 
primary or secondary haematologic prophylaxis, the most 
frequent complication of Haemophilia is the haemophilic 
arthropathy in specific joints, called “target joints” [59]. 
The most involved joint is the knee, and often the quality of 
life is poor due to the severity of symptoms and functional 
impairment: conservative treatments and minimally invasive 
procedures are rarely useful in such cases [60-61]. In the 
recent decades a high increase of the TKA performed in such 
patients has been recorded, given the fact that major surgery 
is the only procedure that may induce adequate pain relief 
and functional recovery [62-63].
VTE is a recognized complication after joint replacement 
surgery, and a prophylaxis is routinely used in patients 
without bleeding disorders. However, in haemophilic 
patients, the pharmacologic VTE prophylaxis is highly 
variable and controversial because of the inherent bleeding 
risk.
A recent review regarding 71 hip or knee replacements in 
42 consecutive patients affected by Haemophilia A or B was 
compared to the literature in order to ascertain the incidence 
of VTE after THA and TKA in the haemophilic population 
[58]. In all patients compression stockings were applied up 
to 6 weeks after surgery; additionally, in 6 cases (10.5%) 
sequential intermittent compression devices were used, 
and 2 (2.8%) received a postoperative low-molecular-weight 
heparin (LMWH) regimen. One patient (1.4%) receiving 
LMWH had a symptomatic VTE ten days after the hip 
replacement for a traumatic proximal femur fracture. None 
of the remainders (70 patients) reported any symptomatic 
VTE within 3 months after surgery. An estimated incidence 
of symptomatic VTE of 0.5% was assessed from the analysis 
of pooled data from several series of haemophilic patients 
undergoing a joint replacement. The conclusion was that 
in patients with Haemophilia, joint replacements can be 
safely performed without a routinary VTE prophylaxis, and 
without an increasing risk of thromboembolic events [58].
Another retrospective study on 38 cases of TKA in 33 
haemophilic patients was reported to evaluate any case of 
DVT pre- and postoperatively by US. No patients performed 
a DVT prophylaxis. Also D-dimer and fibrinogen degradation 
product were measured before and after surgery. No case of 
DVT was found in either pre- or postoperative examinations 
[64]. 
This approach has been safely adopted in many series and not 
only for knee surgery, but also for other major procedures, 
as Total Hip Arthroplasty (THA)[65].
Peculiar conditions in which a VTE prophylaxis may be not 
indicated is the presence of inhibitors, antibodies against 
recombinant factors developed by some patients, able 
to limit the efficacy of clotting factors [66-67]. In such 
patients, the high risk of bleeding is more consistent than 
the risk of VTE. However, the high doses of bypassing agents 
(recombinant factor VII) used to activate the coagulative 
cascade may induce a variable risk requiring a strict and 
multidisciplinary daily evaluation in dedicated centres by 
tailored administration protocols.
To reduce the risk of VTE in inhibitor patients undergoing 
major orthopaedic surgery, the use of non-pharmacologic 
measures, such as standard compression stockings, 
mechanical prophylaxis, and early functional recovery seem 
to be appropriate. 
CONCLUSIONS 
The synthesis of recommendation for VTE prophylaxis 
in knee replacement has been provided by guidelines 
produced in the recent past years by international scientific 
societies [66-67]. The American college of Chest Physicians 
antithrombotic and prevention of thrombosis guidelines [69] 
suggests that in patients undergoing TKA the administration 
of LMWH, fondaparinux , apixaban , dabigatran , rivaroxaban 
, LDUH , adjusted dose warfarin  of finally aspirin has grade 1 
B recommendation, while  intermittent compression devices 
(ICPD) has a grade 1c recommendation.  The use of LMWH 
(with or without ICPD) is preferred to other drugs with a 
grade 2 B recommendation.  LMWH should be preferred to 
other agents in patients at high risk of bleeding. Since a non-
adherence rate between 13 and 27% has been demonstrated 
in patients treated with  LMWH or  fondaparinux. direct oral 
anticoagulants should be considered in patients with expected 
poor adherence to parenteral route of administration. The 
treatments should be started either 12 or more hours 
before surgery or 12 hours or more after. Combination of 
pharmacological prophylaxis and ICPD for at least 18 h/
day has a grade 2 C recommendation.  ICPD alone may be 
considered for patients at high risk of bleeding.  IVC filters 
are not recommended for prophylaxis of thromboembolism 
in patients undergoing major orthopaedic surgery, even 
in the case of high risk of bleeding or contraindication to 
mechanical prophylaxis.  American Academy of Orthopedic 
Surgeons (AAOS) guidelines for the prevention of venous 
thromboembolism (VTE) in patients undergoing hip or 
knee surgery [67] evaluate the efficacy of various agents 
in preventing pulmonary embolus rejecting asymptomatic 
DVT as end point.  The AAOS guidelines accept the use 
of aspirin combined with mechanical compression devices, 
and low-dose warfarin therapy. These guidelines in synthesis 
express a major concern with the risks associated with 
anticoagulation therapy.  However as expressed by ACCP 
guidelines randomized data clearly demonstrated a decrease 
of both DVT and PE by thromboprophylaxis.  Moreover the 
AAOS recommended routine preoperative assessment for 
risk of PE and bleeding and stratified their recommendations 
for thromboprophylaxis according to whether patients are 
“standard risk” or “high risk” for PE and bleeding. They did 
Rostagno, et al.: DVT prophylaxis in TKR
46  Prog Orthop Sci ● 2016 ● Vol 2 ● Issue 4
not discuss the issue of dose adjustments in the elderly or 
those with renal dysfunction, which are the most important 
indicators of high bleeding risk.
Low molecular weight heparin at European dosage (4000 
IU) started before surgery is the usual regimen adopted in 
elective knee arthroplasty in our clinical practice while direct 
oral anticoagulants are prescribed in selected cases with 
expected poor compliance to parenteral agents. 
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